Effect on a platelet adhesiveness in diabetics after long term treatment a new oral hypoglycemic agent, gliclazid
| Autor: | D Maitre, F Coce, Z Turk, Z Rubinjoni, Z. Skrabalo, D Mustovic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1978 |
| Předmět: |
Adult
Blood Glucose Male Drug medicine.medical_specialty Long term treatment Dose media_common.quotation_subject Blood sugar Pharmacology Platelet Adhesiveness Internal medicine Diabetes mellitus Platelet adhesiveness Diet Diabetic Diabetes Mellitus medicine Humans Gliclazide media_common Clinical Trials as Topic business.industry Body Weight General Medicine Middle Aged medicine.disease Sulfonylurea Compounds Endocrinology Female platelet adhesiveness diabetes gliclazid business Oral hypoglycaemic medicine.drug |
| Popis: | Gliclazide is an oral hypoglycaemic agent which has been shown in animal models to reduce platelet adhesiveness. In this study, 50 patients with maturity onset diabetes treated with gliclazide (80 mg/day) were followed up for 6 months to 1 year to assess the effect on platelet adhesiveness and control of blood sugar. A significant fall in mean platelet adhesiveness from 29% before treatment to 19.5% after 1 year (p less than 0.001) was achieved without any deleterious effect on normal haemostasis. The drug was well tolerated and achieved a satisfactory control of blood sugar levels at the dosages used. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|